{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T04:09:47Z","timestamp":1785816587081,"version":"3.56.0"},"reference-count":23,"publisher":"The Journal of Health Economics and Outcomes Research","issue":"1","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["jheor.org"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec id=\"background\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Peripheral T-cell lymphomas (PTCLs) are a rare and heterogeneous group of non-Hodgkin lymphomas associated with aggressive clinical course and suboptimal outcomes. PTCL accounts for a higher proportion of non-Hodgkin lymphoma cases in Japan compared with Western countries; however, real-world evidence on treatment patterns, healthcare resource utilization (HRU), and costs in Japan is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"objectives\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To describe real-world patient characteristics, treatment patterns, HRU, and costs among patients with PTCL in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"methods\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective observational study used administrative claims data from the Medical Data Vision database in Japan. Adult patients diagnosed with PTCL between September 2012 and August 2022 were identified. Patients were categorized as receiving nonsystemic therapy or systemic therapy and stratified by lines of therapy. Patient demographics, comorbidities, treatment regimens, time on treatment, HRU, and healthcare costs, measured per patient per month, were analyzed descriptively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"results\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 910 patients identified, 71.3% received systemic treatment and 28.7% received nonsystemic therapy, most receiving corticosteroids only. Mean age at diagnosis was 69.8 years; 70% of patients were at least 65 years old. Key comorbidities included peptic ulcer disease, congestive heart failure, and diabetes. PTCL\u2013not otherwise specified and angioimmunoblastic T-cell lymphoma accounted for over 75% of subtypes. First-line therapy was mainly cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like regimens; later lines were more heterogeneous and of shorter duration. Mogamulizumab and brentuximab vedotin were used in 4.16% and 10.48% of patients, respectively. Stem cell transplantation was infrequent (6.3%). Median per patient per month PTCL-related total healthcare cost was $9712; median drug ($7056.9) and hospitalization costs ($5177.7) were the main contributors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"discussion\">\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These findings demonstrate substantial clinical and economic burden among PTCL patients in Japan. Treatment heterogeneity and short duration in later lines of therapy highlight ongoing therapeutic challenges.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"conclusions\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>High economic burden of PTCL treatment underscores the need for more effective, tolerable, and less costly therapeutic strategies for treating PTCL patients in Japan.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.36469\/001c.161191","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T20:11:21Z","timestamp":1781208681000},"update-policy":"https:\/\/doi.org\/10.36469\/00001","source":"Crossref","is-referenced-by-count":2,"title":["Peripheral T-cell Lymphoma in Japan: Real-World Patient Characteristics, Treatment Patterns, Healthcare Resource Utilization, and Costs"],"prefix":"10.36469","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3641-9738","authenticated-orcid":true,"given":"Charles","family":"Dharmani","sequence":"first","affiliation":[{"name":"Daiichi Sankyo, Inc.","department":["Epidemiology, Clinical Safety and Pharmacovigilance"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2470-8276","authenticated-orcid":false,"given":"Oluwatosin","family":"Fofah","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc.","department":["Epidemiology, Clinical Safety and Pharmacovigilance"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6469-9936","authenticated-orcid":false,"given":"Pingping","family":"Qu","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc.","department":["Data and Statistical Sciences Centre for RWE"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1671-0881","authenticated-orcid":false,"given":"Zoe","family":"Jiang","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc.","department":["Data and Statistical Sciences Centre for Data Engineering"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3536-4033","authenticated-orcid":false,"given":"Jingjian","family":"Wang","sequence":"additional","affiliation":[{"name":"DeltaMed Solutions, Inc","department":["Data and Statistical Sciences Centre for Data Engineering"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0702-8778","authenticated-orcid":false,"given":"Li","family":"Li","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc.","department":["Data and Statistical Sciences Centre for Data Engineering"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3578-4007","authenticated-orcid":false,"given":"Yijing","family":"Tao","sequence":"additional","affiliation":[{"name":"DeltaMed Solutions, Inc","department":["Data and Statistical Sciences Centre for Data Engineering"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7311-3020","authenticated-orcid":false,"given":"Lin","family":"Song","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Co., Ltd","department":["Data Intelligence Department"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22273","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"issue":"3","key":"ref1","doi-asserted-by":"publisher","first-page":"285","DOI":"10.6004\/jnccn.2022.0015","article-title":"T-cell lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"S. M. Horwitz","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"ref2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1182\/hematology.2024000670","article-title":"The role of stem cell transplant (auto and allo) in PTCL and CTCL","volume":"2024","author":"P. Dreger","year":"2024","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"9","key":"ref3","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1634\/theoncologist.2017-0524","article-title":"Recent advances in the treatment of peripheral T-cell lymphoma","volume":"23","author":"K. Laribi","year":"2018","journal-title":"Oncologist"},{"issue":"9","key":"ref4","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1002\/cncr.31861","article-title":"The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in \ufb01rst complete remission: report from COMPLETE, a prospective, multicenter cohort study","volume":"125","author":"S. I. Park","year":"2019","journal-title":"Cancer"},{"issue":"15","key":"ref5","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.2217\/fon-2023-0615","article-title":"Real-world treatment patterns, healthcare resource utilization and costs among patients with peripheral T-cell lymphoma","volume":"20","author":"C. Dharmani","year":"2024","journal-title":"Future Oncol"},{"issue":"4","key":"ref6","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2217\/fon-2021-1032","article-title":"The clinical and economic burden of peripheral T-cell lymphoma: a systematic literature review","volume":"18","author":"A. O. Ashaye","year":"2022","journal-title":"Future Oncol"},{"issue":"suppl 1","key":"ref7","first-page":"S34","article-title":"Trends in hospitalization length of stay and costs in patients with peripheral T-cell lymphoma (PTCL): analysis of US national in-patient data for 2015","volume":"21","author":"S. Aggarwal","year":"2018","journal-title":"Value Health"},{"issue":"1","key":"ref8","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.clml.2020.07.011","article-title":"Health care resource utilization and costs among medicare beneficiaries newly diagnosed with peripheral T-cell lymphoma: a retrospective claims analysis","volume":"21","author":"A. Shah","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"ref9","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1080\/13696998.2016.1187622","article-title":"Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data","volume":"19","author":"C. Burudpakdee","year":"2016","journal-title":"J Med Econ"},{"key":"ref10","article-title":"About MDV Database, Japan","author":"Medical Data Vision (MDV) Database"},{"issue":"6","key":"ref11","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41568-020-0247-0","article-title":"Peripheral T cell lymphomas: from the bench to the clinic","volume":"20","author":"D. Fiore","year":"2020","journal-title":"Nat Rev Cancer"},{"issue":"282","key":"ref12","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Non-parametric estimation from incomplete observations","volume":"53","author":"E. L. Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4612-4348-9","article-title":"Statistical Models Based on Counting Processes","author":"P. K. Andersen","year":"1993"},{"issue":"62","key":"ref14","doi-asserted-by":"publisher","first-page":"101646","DOI":"10.1016\/j.lanwpc.2025.101646","article-title":"Epidemiology of mature T-cell and NK-cell neoplasms: east and west","volume":"14","author":"Y. L. Kwong","year":"2025","journal-title":"Lancet Reg Health West Pac"},{"issue":"16","key":"ref15","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s40265-022-01800-5","article-title":"Valemetostat tosilate: first approval","volume":"82","author":"S. J. Keam","year":"2022","journal-title":"Drugs"},{"issue":"11","key":"ref16","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1080\/10428190802455867","article-title":"Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States","volume":"49","author":"A. N. Abouyabis","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"ref17","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1080\/17474086.2020.1770590","article-title":"Contemporary strategies to improve outcomes for peripheral T-cell lymphoma patients following the failure of first-line therapy","volume":"13","author":"A. Kallam","year":"2020","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"ref18","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00277-020-04308-8","article-title":"Increased incidence of adult T cell leukemia-lymphoma and peripheral T cell lymphoma-not otherwise specified with limited improvement in overall survival: a retrospective analysis using data from the population-based Osaka Cancer Registry","volume":"100","author":"S. Fuji","year":"2021","journal-title":"Ann Hematol"},{"issue":"4","key":"ref19","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/bjh.12659","article-title":"Differences in incidence and trends of haematological malignancies in Japan and the United States","volume":"164","author":"D. Chihara","year":"2014","journal-title":"Br J Haematol"},{"issue":"3","key":"ref20","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/PPO.0000000000000452","article-title":"Diagnosis, risk stratification, and treatment of peripheral T-cell lymphomas: past and present","volume":"26","author":"W. B. Pearse","year":"2020","journal-title":"Cancer J"},{"issue":"1","key":"ref21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3960\/jslrt.22034","article-title":"Prognostic indices for peripheral T-cell lymphoma-not otherwise specified and adult T-cell leukemia\/lymphoma: From past to future","volume":"63","author":"K. Ishitsuka","year":"2023","journal-title":"J Clin Exp Hematop"},{"issue":"11","key":"ref22","doi-asserted-by":"publisher","first-page":"e517","DOI":"10.1016\/S1470-2045(14)70202-5","article-title":"Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma","volume":"15","author":"K. Ishitsuka","year":"2014","journal-title":"Lancet Oncol"},{"issue":"18","key":"ref23","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1182\/blood.2023021789","article-title":"Current and upcoming treatment approaches to common subtypes of PTCL (PTCL, NOS; ALCL; and TFHs)","volume":"144","author":"A. J. Moskowitz","year":"2024","journal-title":"Blood"}],"container-title":["Journal of Health Economics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jheor.org\/article\/161191-peripheral-t-cell-lymphoma-in-japan-real-world-patient-characteristics-treatment-patterns-healthcare-resource-utilization-and-costs","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T20:15:09Z","timestamp":1785183309000},"score":1,"resource":{"primary":{"URL":"https:\/\/jheor.org\/article\/161191-peripheral-t-cell-lymphoma-in-japan-real-world-patient-characteristics-treatment-patterns-healthcare-resource-utilization-and-costs"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.36469\/001c.161191","relation":{},"ISSN":["2327-2236"],"issn-type":[{"value":"2327-2236","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]}}}